Literature DB >> 8263074

Cerebral uptake of 99mTc-bicisate in patients with cerebrovascular disease in comparison with CBF and CMRO2 measured by positron emission tomography.

F Shishido1, K Uemura, M Murakami, A Inugami, T Ogawa, H Fujita, E Shimosegawa, I Kanno, Y Aizawa, K Nagata.   

Abstract

The regional brain uptake of 99mTc-N,N'-(1,2-ethylenediyl)bis-L-cysteine diethyl ester (99mTc-bicisate) measured by single photon emission computed tomography (SPECT) was compared with the regional CBF and CMRO2 measured by positron emission tomography in patients with cerebrovascular disease. Nine patients with the diagnosis of cerebral ischemic disorders (n = 7) or cerebral hemorrhage (n = 2) were studied. 99mTc-Bicisate brain uptake correlated with CBF and CMRO2. However, 99mTc-bicisate uptake did not reflect CBF in the single lesion showing luxury perfusion, which seemed to resemble a CMRO2 image. Though quantitative analysis showed the nonlinear correspondence of 99mTc-bicisate brain uptake with CBF and CMRO2, this correspondence could be corrected into a more linear relationship using a correction factor. 99mTc-Bicisate washout from the brain had no correlation to CBF and CMRO2. This diffuse decreasing washout rate was approximately 15% during the first hour after injection. By using the lipophilic fraction of arterial blood and a linearized correction of 99mTc-bicisate SPECT images, the feasibility of obtaining a factor-related CBF and CMRO2 was suggested from our data. These results suggested that 99mTc-bicisate had good characteristics for routine clinical use with SPECT to display the brain function in patients with neurological disorders.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8263074

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  7 in total

1.  The cerebrovascular response to traditional acupuncture after stroke.

Authors:  J D Lee; J S Chon; H K Jeong; H J Kim; M Yun; D Y Kim; D I Kim; C I Park; H S Yoo
Journal:  Neuroradiology       Date:  2003-08-27       Impact factor: 2.804

2.  Brain single-photon emission CT studies using 99mTc-HMPAO and 99mTc-ECD early after recanalization by local intraarterial thrombolysis in patients with acute embolic middle cerebral artery occlusion.

Authors:  K Ogasawara; A Ogawa; M Ezura; H Konno; M Suzuki; T Yoshimoto
Journal:  AJNR Am J Neuroradiol       Date:  2001-01       Impact factor: 3.825

3.  Visualizing prolonged hyperperfusion in post-stroke epilepsy using postictal subtraction SPECT.

Authors:  Kazuki Fukuma; Katsufumi Kajimoto; Tomotaka Tanaka; Shigetoshi Takaya; Katsuya Kobayashi; Akihiro Shimotake; Riki Matsumoto; Akio Ikeda; Kazunori Toyoda; Masafumi Ihara
Journal:  J Cereb Blood Flow Metab       Date:  2020-02-16       Impact factor: 6.200

4.  Simplified quantification of regional cerebral blood flow with 99mTc-ECD SPECT and continuous arterial blood sampling.

Authors:  Y Yonekura; K Ishizu; H Okazawa; F Tanaka; N Hattori; N Sadato; T Tsuchida; S Nishizawa; N Tamaki; T Nagamine; J Konishi; H Shibasaki
Journal:  Ann Nucl Med       Date:  1996-05       Impact factor: 2.668

5.  Discrepant 99mTc-ECD images of CBF in patients with subacute cerebral infarction: a comparison of CBF, CMRO2 and 99mTc-HMPAO imaging.

Authors:  F Shishido; K Uemura; A Inugami; T Ogawa; H Fujita; E Shimosegawa; K Nagata
Journal:  Ann Nucl Med       Date:  1995-08       Impact factor: 2.668

6.  Lassen's equation is a good approximation of permeability-surface model: new α values for ⁹⁹mTc-HMPAO and ⁹⁹mTc-ECD.

Authors:  Masashi Kameyama
Journal:  J Cereb Blood Flow Metab       Date:  2014-04-16       Impact factor: 6.200

7.  Optimal Brain 99mTc-Ethyl Cysteinate Dimer SPECT Imaging and Analysis to Detect Misery Perfusion on 15O PET Imaging in Patients With Chronic Occlusive Disease of Unilateral Major Cerebral Artery.

Authors:  Yoshiyasu Matsumoto; Kohki Oikawa; Jun-Ichi Nomura; Daigo Kojima; Sotaro Oshida; Masakazu Kobayashi; Kazunori Terasaki; Yoshitaka Kubo; Kuniaki Ogasawara
Journal:  Clin Nucl Med       Date:  2017-07       Impact factor: 7.794

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.